Purpose To develop an experimental model to assess the feasibility of polar body preimplantation genetic diagnosis without requiring oocyte fertilization. Methods First polar body was removed from donated oocytes and second polar body was biopsied after parthenogenetic activation. Molecular analysis on both polar bodies involved a fluorescent multiplex polymerase chain reaction of shorttandem repeat markers, closely linked to genes of interest. Main outcome measures were: allele segregation through polar bodies and haploid nucleus, recombination rates between alleles and frequency of Allele Drop Out. Results Twenty-six out of 39 oocytes extruded a second polar body after activation. Ninety-two percent of the first polar bodies and 20 out of 26 (77%) second polar bodies were successfully amplified. Eighty percent of first polar bodies were heterozygous for CFTR and 55% for HBB. Analysis of second polar bodies predicted the genotype of the oocytes in case of heterozygous first polar body, and validated results in homozygous cases. Frequency of allele drop out was 4%.
Introduction
Pre-implantation genetic diagnosis (PGD) has become an established clinical approach for prevention of genetic disorders. In this field, polar body analysis together with blastomere analysis has gained increasing importance in recent years.
Following its first application in 1990 [1] , PGD has become an important complement to the presently available approaches for prevention of genetic disorders and a conventional clinical option in reproductive medicine. Since then, the number of centres performing PGD has risen steadily, and new applications and methodologies are introduced regularly [2] . The range of genetic defects which can be diagnosed has expanded dramatically and now includes numerical and structural chromosomal abnormalities [3, 4] and most of the common single gene disorders (SGDs) [5] [6] [7] .
PGD is usually performed by testing single blastomeres removed from cleavage-stage embryos (6-8 cells) . An alternative approach is represented by first (1 PB) [8] and second (2 PB) polar body (PB) testing [9, 10] . Analysis of PBs might be considered an ethically preferable way to perform PGD for couples with moral objections to any potential discarding or micromanipulation of embryos [11] . It may also be an acceptable alternative for countries in which genetic testing of the embryos is prohibited [12] , precluding the ethical debate concerning biopsy of human embryos. To date, PGD has been performed for the above purposes after fertilization of oocytes, by genetic analysis of the 1 PB, or sequential analysis of the 1 PB and 2 PB, allowing only those that are predicted to be normal to proceed to syngamy [9, 10] .
Research in the field of human embryology presents a series of specific limits related to ethical concerns. Experimental models based on parthenogenetic activation are entirely based on female gametes and therefore would overcome many of the ethical limitations to research on human embryos. Moreover these models offer an interesting and valuable tool to evaluate the developmental potential of oocytes exposed to experimental conditions in the first phases of in vitro culture [13] . We recently validated the use of human parthenotes as an experimental model by performing a direct comparison of the in vitro development between fertilized and activated oocytes and confirming that parthenogenetic activation closely mimics the results obtainable with normal fertilization [14] ; this model was efficiently applied to oocyte cryopreservation experimental procedures [15, 16] . On the other hand, the specific genetic constitution of parthenotes makes them chromosomically unstable and raises doubts about the reliability of the model during long term culture, especially when cells deriving from parthenotes are plated and studied as embryonic stem cells [17] . However, parthenogenesis remains a very useful tool to mimic oocyte chromosome segregation through meiosis and development in the first stages immediately after fertilization; in this phases, due to the transcriptional quiescence of the embryonic genome until the four-cell stage, the development depends on oocyte competence only [16, 18] . Haploid parthenotes with first and second polar bodies can be obtained through parthenogenetic activation offering a very interesting tool to validate polar body PGD without wasting zygotes or embryos. The importance of obtaining haploid reconstruction with both first and second polar bodies is crucial for an experimental model as the analysis of the first polar body alone can not take into account all variables determining the result, such as recombination between homologous chromosomes (Fig. 1) .
The aim of the present work is to test an optional experimental model that does not require fertilization and that resembles the dynamics of chromosome segregation and crossover during meiosis. In this model, after the molecular analysis on the first polar body (1 PB), the second polar body (2 PB) and the haploid nucleus can be obtained in order to have a complete genetic analysis and validate molecular results. Indeed, 2 PB analysis is useful to confirm a diagnosis of homozygous 1 PB or to predict which maternal allele will be present in the oocyte in case Chromosomes of a homologous pair and a hypothetic polymorphic genetic marker is depicted in the heterozygous configuration "A" and "a". Left-hand side of the figure: as no crossing over involved the genetic marker during first metaphase, the first polar body (1 PB) contains both copies of one allele and the mature haploid gamete will carry the alternate configuration. In this case, 1 PB analysis can predict oocyte genotype. Right-hand side of the figure: crossing over occurred between the centromere and the polymorphic marker. Both "A" and "a" alleles are retained in the oocyte and 1 PB; the genotype of the gamete can be predicted only after the extrusion of the second polar body (2 PB). This generally occurs after sperm entry into the egg but can be experimentally induced with parthenogenetic activation of heterozygous 1 PB (Fig. 1) . Our parthenogenesis-based model, due to the absence of a paternal genome, is intended for research use only.
Materials and methods

Patients and oocyte retrieval
Fresh oocytes were obtained following controlled ovarian hyperstimulation using a protocol with GnRH antagonist (Cetrotide®; Merck-Serono, Rome, Italy). Ovarian hyperstimulation was achieved administering recombinant FSH (rFSH, Gonal-F®; Merck-Serono, Rome, Italy). Ovarian responsiveness and follicular development were monitored via ultrasonography and serum estradiol-17β assay. When at least three follicles with a mean diameter of ≥18 mm were present, 250 μg of hCG (Ovitrelle®; Merck-Serono, Rome, Italy) were administered to the patients.
Oocyte retrieval was performed via transvaginal aspiration of the follicles 36 h after hCG. During ovum pick-up, oocytecumulus complexes were immediately separated from follicular fluid, washed in flushing medium and transferred to 1 mL of IVF medium (Quinn's Advantage® Protein Plus Fertilization Medium; Sage, Trumbull, CT). Following a 3-hour incubation at 37°C in an atmosphere of 5% CO 2 in air, cumuli oophori Fig. 2 Example of an electropherogram (GeneScan) obtained after parthenogenetic activation of an oocyte. First polar body (1 PB) was heterozygous and corresponding alleles segregated into second polar body (2 PB) and haploid nucleus. Three markers are shown: D7S486, Int8-2 (IVS8CA) and D7S847. "DNA" refers to control DNA obtained from maternal somatic cells. Numbering indicates allele length in base pairs and asterisk * marks the presumptive "affected" allele were completely removed from all oocytes by pipetting them through 170-μm internal diameter pipettes (Flexipet; Cook, Bloomington, IN), after a brief exposure to 40 IU/mL of hyaluronidase (Sage) in gamete handling medium (Quinn's Advantage® Medium with Hepes; Sage). According to Italian law and characteristics of the couples, an adequate number of metaphase II (MII) oocytes was chosen to carry out routine ICSI procedure and subsequent embryo transfer. Cryopreservation of good-quality supernumerary oocytes is routinely offered in our Unit. If declining this offer, patients were asked to participate in the present study. The study was approved by the local Institutional Review Board and informed consent was obtained from participants.
PB biopsy and analysis
After mechanical conventional partial zona dissection [19] , 1PBs were removed from spare donated MII oocytes and immediately transferred to proteinase K lysis buffer [20] for subsequent molecular analysis. After centrifugation at low speed in a microfuge for few seconds, the samples were covered with one drop of mineral oil and incubated at 45°C for 15 min in a thermal cycler. Proteinase K was then inactivated at 96°c for 20 min, which was the beginning of the hot start polymerase chain reaction PCR; at this time a PCR mix was added (described below). Parthenogenetic activation was conducted on biopsied oocytes through exposure to 5 μM ionomycin in IVF medium for 5 min at 37°C, 5% CO 2 in the dark (standard conditions). Oocytes were then washed three times in fresh culture medium (Quinn's Advantage® Protein Plus Cleavage Medium; Sage), placed separately in 40-μL microdrops of the same medium under mineral oil, and cultured under standard conditions. After 18-20 h, oocytes were evaluated for signs of activation. Oocytes showing one enlarged pronucleus and extrusion of a 2 PB were considered activated; 2PBs were biopsied and treated as 1PBs. After the biopsy of the 2 PB, the haploid nucleus of the oocyte was isolated in an embryo-biopsy pipette with gentle aspiration through the cytoplasm. The molecular analysis of the nucleus was used by confirm the prediction made on the 1 PB and 2 PB.
The molecular analysis was based on a fluorescent multiplex PCR of highly polymorphic short-tandem repeat (STR) markers, closely linked to the disease-causing gene. In this set of experiments, a panel of nine highly polymorphic STR markers flanking 'Cystic Fibrosis Transmembrane Conductance Regulator' (CFTR) gene and a panel of twelve highly polymorphic STR markers flanking 'Hemoglobin Beta' (HBB) gene were selected for haplotype analysis, namely: D7S486, D7S522, D7S633, D7S655, D7S677, (IVS17bTA),  D7S847, D11S4146, BSTR, BTG, D11S4181, D11S1758,  D11S998, D11S1871, D11S1760, D11S1338, D11S1241 , D11S1323, D11S1997. The sensitivity and specificity of DNA amplification was improved by using a nested PCR method. With this method the larger fragment produced by the first round of PCR is used as a template for the second round of PCR, using nested fluorescent primers. The best results are obtained by using lower stringency, 5% dimethyl sulphoxide (DMSO) and a longer annealing time during the first round of PCR, and higher stringency in the second round [21] . Lysed samples were placed into a thermal cycler and amplified (first round) using the first round PCR master mix, consisting of 10X PCR buffer, 8 mM dNTPs, 50 mM MgCl 2 , 3 μl DMSO, 1.5 U Taq polymerase, H 2 O and the set of outside upstream and downstream primers for CFTR/HBB STR, under mineral oil. First round PCR was performed as follows: 72°C for 7 min (hot start); then: 95°C for 3 min, 30 cycles at: 95°C for 30 s, 55°C for 1 min and 30 s, 72°C for 45 s; 72°C for 10 min. After the completion of the first round of amplification, an aliquot of 2 μl of the resulting first round PCR product was transferred into a 0.5 ml tube with 48 μl of the fresh second round PCR master mix, containing 10X PCR buffer, 8 mM dNTPs, 50 mM MgCl 2 , 1.5 μl DMSO, 1.5 U Taq polymerase, H 2 O and nested upstream and downstream primers. In contrast to the first round, each tube contained singular pairs of specific nested primers. The samples were amplified as follows: 94°C for 3 min, 30 cycles at 94°C for 30 s, 55°C for 30 s, 72°C for 30 s; 72°C for 10 min. Following nested amplification, PCR products were analyzed by 8% poly-acrilamide gel electrophoresis (PAGE) and then by direct fragment size analysis on a 3130XL ABI sequencing analyzer (Applied Biosystems Italia, Monza, Italy) (Fig. 2) .
STR markers linked to both genes were defined "informative" when determined to be heterozygous from haplotype analysis carried out on maternal DNA extracted from follicular fluid granulosa cells. Based on three or more informative markers, genetic analysis was performed on the 1 PB and 2 PB.
The co-amplification of several markers was used to increase the assay accuracy by avoiding misdiagnosis from allele dropout of individual markers.
Positive and negative controls for each genetic testing were included in the analysis.
A sample of culture medium from each droplet containing a PB was tested as a media blank to verify the absence of genetic material in the culture media.
The optimization of the multiplex PCR protocols was initially performed on single cumulus cells, collected from ADO Allele Drop Out donor women, to determine the best condition for reliable and reproducible results from single-cell amplification. Exact Fisher's confidence intervals were computed for rates and reported as 95% Confidence Interval (95%CI)
Results
Thirty-nine donated oocytes were selected from 13 women. After 1 PB removal, oocytes were subjected to parthenogenetic activation and 26 (67%, 95%CI: 50-81%) extruded the 2 PB. Amplified first polar bodies from ten out of 13 oocytes that failed to extrude 2 PB following parthenogenetic activation were heterozygous while three were homozygous for evaluated markers. PCR results were available for 57 out of 65 analysed PBs (88%, 95%CI: 75-93%) since three out of 39 1PBs and five out of 26 2 PB were unsuccessfully PCR-amplified. Table 1 shows results for the 26 activated oocytes.
Results from 1PBs showed that 80% (95%CI: 52-96%) of 1PBs were heterozygous for CFTR markers and 55% (95%CI: 23-83%) of 1PBs were heterozygous for HBB markers, thus resulting in a high percentage of crossover recombination for both genes. Six out of 152 evaluated STR markers resulted in PCR amplification failure of one allele, thus revealing an allele drop out rate of 4% (95%CI: 1-8%). No more than one case of allele dropout for individual PBs was observed, as confirmed by the presence of other informative flanking markers. Tables 2 and 3 show detailed information regarding patients' markers (granulosa cells), 1 PB, 2 PB andcorresponding pronucleus analysis as well as allele drop out datapresented per oocyte.
For both genes, 2 PB analysis consistently permitted the prediction of the genotype in the case of a heterozygous 1 PB and confirmed the 1 PB results in cases of homozygosity.
In five cases, a haploid nucleus was collected and analyzed after the 2 PB biopsy. PCR results confirmed the presence of the missing haplotype, as predicted from 1 PB and 2 PB analysis (Fig. 2) .
Discussion
In the present study we evaluated a model of parthenogenetic activation of human oocytes in order to assess the feasibility of PGD for monogenic disorders on human oocytes in our laboratory.
Through this novel experimental model we confirmed that the oocyte genotype can be predicted also in the presence of allele dropout if an adequate number of informative markers are evaluated. A reliable haplotype was obtained in 36/39 (92%) oocytes according to 1 PB analysis and confirmed in a subgroup (18/26, 69%) of activated oocytes through 2 PB genotyping. If molecular analysis is limited to the 1 PB and it results in a heterozygous prediction, no assertion on the oocyte genotype can be made. It would be then be mandatory to analyze the 2 PB to predict which allele will form the genotype of the female gamete. In a clinical setting this can be obtained exclusively after fertilization as the 2 PB is extruded following sperm entry into the oocyte. In order to confirm the ability and consistency of a monogenic disorder assay to predict the oocyte's genotype, a research model that avoids the use of human zygotes may be particularly valuable. Moreover, after the biopsy of the 2 PB, the haploid nucleus of the oocyte can be isolated and analyzed to confirm the prediction made on 1 PB and 2 PB. As a proof of principle, we biopsied the haploid nucleus from 5 activated oocytes in which heterozygosity resulted in the 1 PB for evaluated markers. In all cases, on the basis of the 2 PB haplotype, the expected allele was found in the nucleus.
In our series, two informative markers were sufficient to reveal every case of ADO. However, according to international guidelines [22] three or more informative markers should be analyzed for an effective clinical application. Regarding detection rate, we did not observe markers behaving better than others do.
The proposed parthenogenesis-based model provides several advantages in the field of pre-conception genetic diagnosis, includes effectiveness and low technology requirements.
Moreover, its application avoids the majority of the arguments against using human zygotes or embryos. Many people regard in vitro-obtained embryos as human beings even though there is a complete lack of consensus on when the moral and legal status of the developing conceptus should be recognized. Numerous national legislatures or guidelines have therefore banned the use of embryos, even supernumerary or discarded, for research purposes. The International Federation of Fertility Societies (IFFS) Surveillance 2007 reports that about half of the 57 surveyed nations indicated that experimentation on human "pre-embryos" is unacceptable [23] . Authorized research is often subjected to time limitations with respect to embryonic developmental stage and special precautions are mandatory for studies involving embryos. Ethical, legal and political concerns on the value of human embryos regulate embryological studies and, similarly to any other study involving patients, impose that research projects are initially examined by Institutional Review Boards, obtain patient consent, and follow international guidelines, such as the World Medical Association Declaration of Helsinki (2000) or World Health Organization Ethical Guidelines (1998) [24, 25] , which are founded on the widespread belief that human embryos should not be created and studied for research purposes only.
Preimplantation genetic screening (PGS) of human embryos for numerical chromosome abnormalities has been proposed for several years without an improvement in live birth rates compared with control groups [26] . The focal explanation is that in many cases the analysed blastomere is not representative of the entire embryo. Moreover, it has been indicated that lack of expertise in technical procedures can significantly affect results in clinical trials evaluating the effect of PGS of embryos on pregnancy outcome [27] . However, since mosaicism is not present at the zygote stage, the ESHRE PGS Taskforce proposes that it would be more fruitful to opt for polar body biopsy [28] . Our parthenogenetic activation model could fit the aims proposed by the ESHRE taskforce such as determining whether biopsy of the first and second polar body enables a timely identification of the chromosomal status of an oocyte. Many centres could benefit from our experimental model in order to obtain experience and training of personnel in PGS and PGD while avoiding the use of embryos or zygotes before clinical application.
It is crucial that centres offering PGD or PGS of oocytes or embryos demonstrate experience with and quality control for performing biopsy and genetic testing. We propose our experimental model based on parthenogenesis for training courses in order to: 1) practice in 1 PB and 2 PB biopsy techniques, 2) perform genetic testing, 3) validate molecular results through comparison of 1 PB and 2 PB, 4) evaluate recombination rate between alleles, 5) assess amplification failure rate and allele drop out rate.
On the other hand, it is worth mentioning that a crucial disadvantage is intrinsic in the preliminary work-up and clinical application of polar body analysis. It can give information about maternal genotype only and can not be proposed in cases of paternally derived dominant disorders. Blastomere biopsy could improve the outcome of the analysis in recessive disorders by testing the paternal contribution and rescuing embryos with the maternal mutation only. Such evidence is highlighted when sequential analysis of the 1 PB and blastomeres is feasible [29] .
Our results showed a high recombination rate including the CFTR gene (80%; 95% CI:52-96%) and the HBB gene (55%: 95%CI: 23-83%). Although it was not the primary aim of the present work and a limited number of oocytes were studied, our data confirm previous results [30, 31] . The rate of 1 PB heterozygosity is representative of rates in fertilized oocytes since 1 PB is extruded before fertilization. This implicates that if only 1 PB is evaluated in the clinical practice, the percentage of cases that would fail to predict oocyte genotype would be as high as the rate of 1 PB heterozygosity.
In conclusion, this model of parthenogenetic activation confirms that polar body-PGD for single gene disorders is feasible, and offers a valuable tool for setting up PGD procedures by using first and second polar bodies from donated parthenogenetically activated oocytes instead of zygotes. The opportunity of investigating all of four copies of genetic information through meiosis allows the estimation of crossover rate between specific sequences and provides a useful tool for training in molecular procedures. High recombination rates in evaluated genes suggest that it is important to analyze both the 1 PB and 2 PB in order to select oocytes carrying the wild type allele. This approach could also avoid the need for a large cohort of oocytes per patient.
